{"symbol": "CNTG", "name": "Centogene", "next_earnings_utc": 1592217000, "next_earnings_period_start_date_utc": 1577750400, "next_earnings_period_end_date_utc": 1585612800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 14092284.41754917, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.3530041063323968, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 2, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "centogene.com", "year_founded": 2006, "street_address": "Am Strande 7", "city": "Rostock", "state": null, "zipcode": "18055", "country": "Germany", "phone_number": "49 381 8011 3500", "short_description": "Centogene N.V. operates as a commercial-stage rare disease company in Europe, Middle East, North America, Latin America, and Asia Pacific.", "long_description": "Centogene N.V. operates as a commercial-stage rare disease company in Europe, Middle East, North America, Latin America, and Asia Pacific. The company operates through two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. The Diagnostics segment provides genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform based on data repository, which includes epidemiologic, phenotypic, and genetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. The company has collaborative research agreement with Shire related for HAE Kininogen assay mass spectrometry testing and screening. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 423443768, "total_enterprise": 406539941, "number_of_employees": 440, "outstanding_shares": 19861340, "eps": -1.42560403813797, "diluted_eps": -1.42560403813797, "earnings_from_cont_operations": -23393158, "gross_profit": 25546831, "cash": 46096467, "total_debt": 30252384, "total_revenue": 54716769, "cash_from_operations": -8721256, "net_income": -23393158, "ebitda": -18463264, "year_low_stock_price": 7.8, "year_high_stock_price": 28.71, "seekingalpha_follower_count": 351, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/CNTG.png"}